Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals Plc ADR (NQ: CNTA )

17.60 +0.30 (+1.73%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Centessa Pharmaceuticals Plc ADR

< Previous 1 2 3 4 5 6 Next >
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Where Centessa Pharmaceuticals Stands With Analysts
Via Benzinga
Centessa Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
From AnaptysBio, Inc.
Via GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
From Centessa Pharmaceuticals plc
Via GlobeNewswire
IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
Oral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and other sleep disorders 
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
From Centessa Pharmaceuticals plc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market. 
Via Benzinga
InMode, Daktronics, Domino's Pizza And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
Enrollment progressing toward interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of study 
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows 
Via News Direct
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 12, 2023
Via Benzinga
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.